Jove
Visualize
Contact Us

Related Experiment Videos

Progesterone receptor antagonists.

Irving M Spitz1

  • 1Institute of Hormone Research, 14 Nili Street, Jerusalem 92548, Israel. Irving@spitz.com

Current Opinion in Investigational Drugs (London, England : 2000)
|November 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mifepristone: Reflections on its Early Clinical Development for Medical Abortion.

Rambam Maimonides medical journal·2026
Same author

Three Giants in the Cradle of Reproductive Medicine; Reproduction Theories of the Seventeenth Century as Discerned by Pregnancy Portraiture in the Oeuvre of Jan Vermeer.

Rambam Maimonides medical journal·2016
Same author

Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century.

Contraception·2010
Same author

Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.

The Journal of clinical endocrinology and metabolism·2010
Same author

Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer.

European journal of endocrinology·2009
Same author

Clinical utility of progesterone receptor modulators and their effect on the endometrium.

Current opinion in obstetrics & gynecology·2009
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Selective progesterone receptor modulators, like mifepristone, offer potential treatments for gynecological conditions. These compounds demonstrate antiproliferative effects on the endometrium and can inhibit ovulation, suggesting contraceptive applications.

Area of Science:

  • Reproductive endocrinology and pharmacology.
  • Development of novel therapeutic agents targeting the progesterone receptor.

Background:

  • Mifepristone, a progesterone receptor antagonist, paved the way for new drug development.
  • Selective progesterone receptor modulators (SPRMs) exhibit a range of agonist/antagonist activities.

Purpose of the Study:

  • To synthesize and evaluate novel selective progesterone receptor modulators (SPRMs).
  • To explore the therapeutic potential of SPRMs in gynecological conditions and oncology.

Main Methods:

  • Synthesis of novel compounds with varying progesterone receptor modulating activities.
  • Preclinical and clinical evaluation of SPRM efficacy and safety profiles.

Main Results:

  • Long-term administration of SPRMs leads to endometrial antiproliferative effects.

Related Experiment Videos

  • Observed effects include amenorrhea and inhibition of ovulation.
  • Mifepristone has the most extensive clinical data, with ongoing studies for other SPRMs.

    • Conclusions:

    • SPRMs show promise for treating uterine fibroids, endometriosis, and dysfunctional uterine bleeding.
    • These agents are being investigated as potential contraceptives.
    • SPRMs may also be valuable in managing steroid-responsive tumors.